<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543334</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2011/JYL-03</org_study_id>
    <secondary_id>2011-A01339-32</secondary_id>
    <nct_id>NCT01543334</nct_id>
  </id_info>
  <brief_title>Antibiotic Concentrations Among Critically Ill Patients</brief_title>
  <acronym>DALI</acronym>
  <official_title>Antibiotic Concentrations Among Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the DALI study is to compare antibiotic concentrations in patient
      blood samples with bacteriological objectives associated with maximum bactericidal activity.
      The antibiotics studied are certain lactams and glycopeptides.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>[antibiotics] in blood versus bactericidal activity</measure>
    <time_frame>1/2 antibiotic dose interval (expected maximum of 4 days; days 1 to 4)</time_frame>
    <description>The primary endpoint for the DALI study is the comparison of antibiotic concentrations in patient blood samples with bacteriological objectives associated with maximum bactericidal activity. The antibiotics studied are certain lactams (endpoint pharmacokinetics 50 and 100% T&gt; MIC) and glycopeptides (100% T&gt; 4xCMI and report ASC0-24/CMI ≥ 350).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[antibiotics] in blood versus bactericidal activity</measure>
    <time_frame>30 minutes before second antibiotic dose (expected maximum of 7 days; days 1 to 7)</time_frame>
    <description>The primary endpoint for the DALI study is the comparison of antibiotic concentrations in patient blood samples with bacteriological objectives associated with maximum bactericidal activity. The antibiotics studied are certain lactams (endpoint pharmacokinetics 50 and 100% T&gt; MIC) and glycopeptides (100% T&gt; 4xCMI and report ASC0-24/CMI ≥ 350).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apache II score</measure>
    <time_frame>at time of blood sampling (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>at time of blood sampling (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIRO score</measure>
    <time_frame>at time of blood sampling (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis at admission</measure>
    <time_frame>Admission to ICU (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indication for antibiotic treatment</measure>
    <time_frame>at time of blood sampling (day 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>did the patient have a surgical procedure in the last 24 hours?</measure>
    <time_frame>at time of blood sampling (day 1)</time_frame>
    <description>yes/no</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">98</enrollment>
  <condition>Administration of Antibiotics in Intensive Care Units</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive care patients with a vein or artery catheter and who are being administered
        antibiotics Can be of the following: Amoxicillin-clavulanic acid, ampicillin,
        piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin,
        cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem;
        Vancomycin, teicoplanin.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient (or his/her &quot;trusted representative&quot;) must have given his/her informed and
             signed consent

          -  Antibiotic treatment is administered with beta-lactams or glycopeptides administered
             continuously or intermittently (Can be of the following: Amoxicillin-clavulanic acid,
             ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin,
             cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem,
             doripenem, ertapenem; Vancomycin, teicoplanin).

          -  A vein or artery catheter is established to facilitate blood sampling (arterial
             catheter is preferred)

        Exclusion Criteria:

          -  None of the above-mentioned antibiotics are administered

          -  Impossible to establish venous or arterial catheter

          -  Consent not given

          -  Patient is pregnant, parturient or breastfeeding

          -  The patient is under tutorship or curatorship

          -  The patient is participating in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Yves Lefrant, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens - Hôpital Nord</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers - Hôtel-Dieu</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Hôpital Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital A Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM - Hôpital Nord</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital St-Roch</name>
      <address>
        <city>Nice</city>
        <zip>06006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Bichat - Claude Bernard</name>
      <address>
        <city>Paris Cedex 18</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital PontChaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intensive care</keyword>
  <keyword>antibiotic levels in blood samples</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

